Phosphatidate phosphatase LPIN1 (LPIN1)

Phosphatidate phosphatase LPIN1, commonly referred to as Lipin-1, is a dual-function protein essential for maintaining lipid homeostasis (UniProt Q14693). It functions primarily as a magnesium-dependent enzyme that converts phosphatidic acid into diacylglycerol, which is a precursor for the synthesis of triacylglycerols and phospholipids (NCBI Gene 23175). In addition to its cytoplasmic enzymatic role, LPIN1 can translocate to the nucleus to serve as a transcriptional coactivator, partnering with factors like PPAR-alpha and PGC-1alpha to promote fatty acid oxidation (PubMed 16439205). This dual role allows LPIN1 to balance lipid storage and utilization depending on the cell's metabolic state. Clinically, LPIN1 is highly significant as mutations in its gene are the most common cause of severe, recurrent rhabdomyolysis in pediatric populations (PubMed 18310261). It is also implicated in the pathogenesis of metabolic syndrome, type 2 diabetes, and lipodystrophy due to its central role in adipocyte differentiation and insulin sensitivity. While no drugs specifically targeting LPIN1 are currently in widespread clinical use, it remains a subject of intense research for treating metabolic disorders and certain types of cancer where lipid signaling is dysregulated. Non-specific inhibitors like propranolol have been used in laboratory settings to study its phosphatase activity, but therapeutic development focuses on more selective modulation.

Other names

Lipin-1PAP1Phosphatidic acid phosphatase 1LPIN1

Dephosphorylation of phosphatidic acid to diacylglycerol and transcriptional coactivation of metabolic genes.